List of works - Sean Khozin

18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors

scientific article published on 4 February 2013

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

scientific article published on 14 July 2013

Advantages of a Truly Open-Access Data-Sharing Model

scientific article

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration

scientific article

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem.

scientific article published on 22 September 2017

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval

scientific article published on 9 January 2018

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

scientific article published on 15 January 2014

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

scientific article

Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.

scientific article published on 26 March 2013

Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period

scientific article

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

scientific article

Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement.

scientific article

INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology

scientific article published on 06 April 2018

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

scientific article

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

scientific article published on 15 June 2017

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

scientific article published on 6 December 2016

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

scientific article

Real-world Data for Clinical Evidence Generation in Oncology

scientific article

Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA.

scientific article published in September 2016

Regulatory watch: From big data to smart data: FDA's INFORMED initiative

scientific article

Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?

scientific article published on 22 May 2015

Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.

scientific article

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

scientific article published on 22 January 2016

The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative

scientific article published on 18 January 2016

The effects of adrenalectomy and aldosterone replacement in transgenic mice expressing antisense RNA to the type 2 glucocorticoid receptor.

scientific article published in November 2002

U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.

scientific article

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

scientific article

Using the hierarchy of control technologies to improve healthcare facility infection control: lessons from severe acute respiratory syndrome.

scientific article published in July 2004

List of works by Sean Khozin

18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

Advantages of a Truly Open-Access Data-Sharing Model

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem.

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.

Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement.

INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

Real-world Data for Clinical Evidence Generation in Oncology

Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA.

Regulatory watch: From big data to smart data: FDA's INFORMED initiative

Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?

Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative

The effects of adrenalectomy and aldosterone replacement in transgenic mice expressing antisense RNA to the type 2 glucocorticoid receptor.

U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

Using the hierarchy of control technologies to improve healthcare facility infection control: lessons from severe acute respiratory syndrome.